Erika Lerch
Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.
Zander T, Pabst T, Schär S, Aebi S, Mey U, Novak U, Lerch E, Rhyner Agocs G, Goede J, Maniecka Z, Hayoz S, Rüfer A, Renner C, Driessen C. Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial. Leukemia 2023; 37:699-701.
Jan 12, 2023Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.
Jan 12, 2023Leukemia 2023; 37:699-701
Zander Thilo, Pabst Thomas, Schär Sämi, Aebi Stefan, Mey Ulrich J M, Novak Urban, Lerch Erika, Rhyner Agocs Gaëlle, Goede Jeroen, Maniecka Zuzanna, Hayoz Stefanie, Rüfer Axel, Renner Christoph, Driessen Christoph
Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
Samaras P, Zander T, Taverna C, Schmidt A, Pabst T, Mey U, Matthes T, Lerch E, Ketterer N, Heim D, Duchosal M, Driessen C, Betticher D, Bargetzi M, Renner C. Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss Med Wkly 2019; 149:w20031.
Apr 3, 2019Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
Apr 3, 2019Swiss Med Wkly 2019; 149:w20031
Samaras Panagiotis, Zander Thilo, Taverna Christian, Schmidt Adrian, Pabst Thomas, Mey Ulrich, Matthes Thomas, Lerch Erika, Ketterer Nicolas, Heim Dominik, Duchosal Michel A, Driessen Christoph, Betticher Daniel C, Bargetzi Mario, Renner Christoph
Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study
Ghilardi G, Ghielmini M, Wannesson L, Lerch E, Samaras P, Schanz U, Passweg J, Stussi G, Kleber M, Gerber B, Rossi D, Schmidt A, Pabst T, Jeker B, Müller R, Cairoli A, Müller A, Bargetzi M, Hitz F, Baldomero H, Heim D, Swiss Blood Stem Cell Transplantation Registry. Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study. Bone Marrow Transplant 2018
Nov 2, 2018Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study
Nov 2, 2018Bone Marrow Transplant 2018
Ghilardi Guido, Ghielmini Michele, Wannesson Luciano, Lerch Erika, Samaras Panagiotis, Schanz Urs, Passweg Jakob R, Stussi Georg, Kleber Martina, Gerber Bernhard, Rossi Davide, Schmidt Adrian, Pabst Thomas, Jeker Barbara, Müller Rouven, Cairoli Anne, Müller Antonia M S, Bargetzi Mario, Hitz Felicitas, Baldomero Helen, Heim Dominik, Swiss Blood Stem Cell Transplantation Registry
Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
Samaras P, Zander T, Taverna C, Pabst T, Mey U, Matthes T, Lerch E, Ketterer N, Hess U, Heim D, Duchosal M, Betticher D, Bargetzi M, Renner C. Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss Med Wkly 2015; 145:w14100.
Feb 21, 2015Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
Feb 21, 2015Swiss Med Wkly 2015; 145:w14100
Samaras Panagiotis, Zander Thilo, Taverna Christian, Pabst Thomas, Mey Ulrich, Matthes Thomas, Lerch Erika, Ketterer Nicolas, Hess Urs, Heim Dominik, Duchosal Michel A, Betticher Daniel C, Bargetzi Mario, Renner Christoph
Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone)
Wannesson L, Samaras P, Renner C, Pabst T, Lerch E, Hess U, Heim D, Cerutti A, Cairoli A, Bargetzi M, Zucca E. Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone). Leuk Lymphoma 2012; 54:36-40.
Jul 9, 2012Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone)
Jul 9, 2012Leuk Lymphoma 2012; 54:36-40
Wannesson Luciano, Samaras Panagiotis, Renner Christoph, Pabst Thomas, Lerch Erika, Hess Urs, Heim Dominik, Cerutti Alessandra, Cairoli Anne, Bargetzi Mario, Zucca Emanuele
A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function
Siano M, Gallino A, Sessa C, Mora O, Leoncini L, Oberson M, Rodriguez-Abreu D, Zucca E, Negretti L, Lerch E, Ghielmini M. A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function. Clinical cancer research : an official journal of the American Association for Cancer Research 2008; 14:7935-9.
Dec 1, 2008A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function
Dec 1, 2008Clinical cancer research : an official journal of the American Association for Cancer Research 2008; 14:7935-9
Siano Marco, Gallino Augusto, Sessa Cristiana, Mora Oreste, Leoncini Leda, Oberson Michel, Rodriguez-Abreu Delvys, Zucca Emanuele, Negretti Laura, Lerch Erika, Ghielmini Michele